US ruling favours Warner Chilcott on Sarafem patent
This article was originally published in Clinica
Executive Summary
Shares of Warner Chilcott (formerly Galen Holdings) jumped by more than 5% after the company announced that it had won a dispute with Teva Pharmaceutical Industries about the infringement of a US patent for Sarafem (fluoxetine). Sarafem is indicated only for the treatment of pre-menstrual dysphoric disorder (PMDD).